SERUM VITAMIN D IN PATIENTS WITH BENIGN, PRIMARY MALIGNANT AND METASTATIC BONE TUMORS

Participant in the process of normal bone remodeling is vitamin D, which, addition, has antiinflammatory (anti-cytokine), anti-proliferative and anti-tumor effects. Objective study to assess level 25-hydroxyvitamin D3 concentration blood serum before start treatment patients with benign, primary malignant metastatic tumors, taking into account polymorbidity. Materials methods. The following were included study: 21 benign pelvic tumors; 52 tumors bones pelvis lower limbs; limbs. control group consisted 22 practically healthy volunteers without chronic diseases. content D was determined by immunochemiluminescence method. results. range from 22.4 29.6 ng/ml, — 7.8 15.9 ones 13.8 15.5 ng/ml. There are no statistically significant differences between histotypes (p > 0.05). Conclusions. Polymorbidity significantly increases deficiency osteogenic sarcoma < According national classification content, have a suboptimal while deficiency.